ALK and neoplasm: Miura Y et al. identified smoking as a predictive marker of response to immune checkpoint inhibitors (ICIs), showed that nonsmokers with EGFR mutated or ALK rearranged tumor did not respond well to ICIs, and suggested patients should not receive ICIs as first-line treatment even though high PD–L1 expression was detected in their tumor cells22.